Curis Inc. (CRIS)
3.24
0.05 (1.57%)
At close: Jan 15, 2025, 1:31 PM
undefined% (undefined)
| Bid | 3.2 |
| Market Cap | 27.43M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -7.77 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.28 |
| Volume | 26,043 |
| Avg. Volume (20D) | 125,654 |
| Open | 3.10 |
| Previous Close | 3.19 |
| Day's Range | 3.10 - 3.29 |
| 52-Week Range | 2.86 - 17.49 |
| Beta | undefined |
About CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize t...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2000
Employees 49
Stock Exchange NASDAQ
Ticker Symbol CRIS
Website https://www.curis.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CRIS stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 609.88% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Curis Inc. is scheduled to release its earnings on Feb 6, 2025,
before market opens.
Analysts project revenue of $2.04M, reflecting a -24.33% YoY shrinking and earnings per share of -1.24, making a -38.92% decrease YoY.
Analysts project revenue of $2.04M, reflecting a -24.33% YoY shrinking and earnings per share of -1.24, making a -38.92% decrease YoY.
